Major stock indexes advanced to end a volatile week of trading, led by Amazon shares. Meanwhile, 10-year Treasury yields hit ...
Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak demand. Read more on MRNA stock here.
The version 7.0 update for Genshin Impact, dubbed “Everwinter Without Mercy,” will launch on August 12, developer miHoYo announced.
I maintain my Strong Buy rating Lam Research (LRCX) with a revised price target of $455 per share. LRCX’s Q4 2026 results exceeded expectations, supporting an increased FWD non-GAAP EPS estimate to $9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results